Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 27 June 2025
First Online: 16 July 2025
Declarations
:
: Not applicable.
: Written consent to publish was provided by interviewee, and a copy of written consent is available for review by the Editor of this journal upon request.
: QX, and AH report no conflicts of interests. DP is a co-founder of the Orphan Therapeutics Accelerator, and has received consulting compensation from the Foundation for NIH and the N of 1 Collaborative. AWL reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. AWL is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, BridgeBio Pharma, n-Lorem, Uncommon Cures, and Vesalius Therapeutics; and an advisor to AACR Oncology Development Fund, Apricity Health, Aracari Bio, BrightEdge Impact Fund, Gondola Bio, Health at Scale, Khora Therapeutics, MIT Proto Ventures, Quantile Health, Ride Therapeutics, Roivant Social Ventures, Swiss Finance Institute, Thalēs, Think Therapeutics, and xCures. During the most recent six-year period, AWL has received speaking/consulting fees, honoraria, or other forms of compensation from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, CME, Enable Medicine, Journal of Investment Management, Lazard, MIT, New Frontier Advisors, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Roivant, SalioGen Therapeutics, Swiss Finance Institute, Think Therapeutics, Vesalius Therapeutics, and WW Norton. In addition, the MIT Laboratory for Financial Engineering, for which AWL serves as director, has received funding support from Critical Path Institute, Schmidt Futures, and Wellcome Leap.
: QX, and AH report no conflicts of interests. DP is a co-founder of the Orphan Therapeutics Accelerator, and has received consulting compensation from the Foundation for NIH and the N of 1 Collaborative. AWL reports personal investments in private biotechnology companies, biotechnology venture capital funds, and mutual funds. AWL is a co-founder and principal of QLS Advisors LLC, a healthcare investments advisor, and QLS Technologies LLC, a healthcare analytics and consulting company; a director of AbCellera, Annual Reviews, BridgeBio Pharma, n-Lorem, Uncommon Cures, and Vesalius Therapeutics; and an advisor to AACR Oncology Development Fund, Apricity Health, Aracari Bio, BrightEdge Impact Fund, Gondola Bio, Health at Scale, Khora Therapeutics, MIT Proto Ventures, Quantile Health, Ride Therapeutics, Roivant Social Ventures, Swiss Finance Institute, Thalēs, Think Therapeutics, and xCures. During the most recent six-year period, AWL has received speaking/consulting fees, honoraria, or other forms of compensation from AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, CME, Enable Medicine, Journal of Investment Management, Lazard, MIT, New Frontier Advisors, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Roivant, SalioGen Therapeutics, Swiss Finance Institute, Think Therapeutics, Vesalius Therapeutics, and WW Norton. In addition, the MIT Laboratory for Financial Engineering, for which AWL serves as director, has received funding support from Critical Path Institute, Schmidt Futures, and Wellcome Leap.
